Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Profits are valuable, but they’re not everything. At StockStory, we help you identify the companies that have real staying power. Keeping that in mind, here are three profitable companies that don’t make the cut and some better opportunities instead.
USANA (USNA)
Trailing 12-Month GAAP Operating Margin: 5.3%
Going to market with a direct selling model rather than through traditional retailers, USANA Health Sciences (NYSE: USNA) manufactures and sells nutritional, personal care, and skincare products.
Why Does USNA Give Us Pause?
- Products aren’t resonating with the market as its revenue declined by 1.7% annually over the last three years
- Subscale operations are evident in its revenue base of $925.9 million, meaning it has fewer distribution channels than its larger rivals
- Performance over the past three years shows each sale was less profitable as its earnings per share dropped by 19% annually, worse than its revenue
USANA is trading at $17.45 per share, or 8.4x forward P/E. Check out our free in-depth research report to learn more about why USNA doesn’t pass our bar.
West Pharmaceutical Services (WST)
Trailing 12-Month GAAP Operating Margin: 20.3%
Founded in 1923 and serving as a critical link in the pharmaceutical supply chain, West Pharmaceutical Services (NYSE: WST) manufactures specialized packaging, containment systems, and delivery devices for injectable drugs and healthcare products.
Why Are We Cautious About WST?
- 4.9% annual revenue growth over the last two years was slower than its healthcare peers
- Expenses have increased as a percentage of revenue over the last five years as its adjusted operating margin fell by 5.8 percentage points
- Eroding returns on capital suggest its historical profit centers are aging
At $317.50 per share, West Pharmaceutical Services trades at 35.8x forward P/E. Read our free research report to see why you should think twice about including WST in your portfolio.
Amneal (AMRX)
Trailing 12-Month GAAP Operating Margin: 13.1%
Founded in 2002 and growing into one of America's largest generic drug producers, Amneal Pharmaceuticals (NASDAQ: AMRX) develops, manufactures, and distributes generic medicines, specialty branded drugs, biosimilars, and injectable products for the U.S. healthcare market.
Why Is AMRX Not Exciting?
- Estimated sales growth of 2.2% for the next 12 months implies demand will slow from its two-year trend
- Underwhelming 4.9% return on capital reflects management’s difficulties in finding profitable growth opportunities
Amneal’s stock price of $13.00 implies a valuation ratio of 13.6x forward P/E. If you’re considering AMRX for your portfolio, see our FREE research report to learn more.
Stocks We Like More
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
